Targets › CYP3A43
7 programs from 7 companies in 9 trials: 3 Phase 2, 2 Phase 1, 2 Phase 3, 2 Phase 4; Infectious disease, Oncology; next expected readout Jan 2027.
A cytochrome P450 monooxygenase involved in the metabolism of xenobiotics such as the psychoactive drugs olanzapine and alprazolam. May be involved in the metabolism of endogenous compounds, although the range of substrates remain largely uncharacterized (Probable). (UniProt, Q9HB55)
Open in Phaseline: the race on CYP3A43, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Mount Sinai Hospital, Canada | Ritonavir Human immunodeficiency virus type 1 protease inhibitor; Cytochrome P450 3A inhibitor | CYP3A4, CYP3A5, CYP3A43, CYP3A7 | Phase 4 | SARS CoV-2 Post-Acute Sequelae | Jan 2027 |
| Gilead Sciences | Cobicistat Cytochrome P450 3A inhibitor | CYP3A4, CYP3A5, CYP3A43, CYP3A7 | Phase 4 | HIV-1-infection; AML, Adult | Jun 2027 |
| University of Oxford | Ritonavir Human immunodeficiency virus type 1 protease inhibitor; Cytochrome P450 3A inhibitor | CYP3A4, CYP3A5, CYP3A43, CYP3A7 | Phase 3 | Pneumonia; COVID-19 | Jan 2027 |
| Haukeland University Hospital | Ritonavir Human immunodeficiency virus type 1 protease inhibitor; Cytochrome P450 3A inhibitor | CYP3A4, CYP3A5, CYP3A43, CYP3A7 | Phase 3 | Post COVID-19 Condition, Unspecified | Jun 2027 |
| Harvard School of Public Health (HSPH) | Ritonavir Human immunodeficiency virus type 1 protease inhibitor; Cytochrome P450 3A inhibitor | CYP3A4, CYP3A5, CYP3A43, CYP3A7 | Phase 2 | HIV | Jun 2029 |
| University of Wisconsin, Madison | Ritonavir Human immunodeficiency virus type 1 protease inhibitor; Cytochrome P450 3A inhibitor | CYP3A4, CYP3A5, CYP3A43, CYP3A7 | Phase 1 | High-Grade Anal Intraepithelial Neoplasia | Jun 2027 |
| University of Miami | Ritonavir Human immunodeficiency virus type 1 protease inhibitor; Cytochrome P450 3A inhibitor | CYP3A4, CYP3A5, CYP3A43, CYP3A7 | Phase 1 | High Grade Glioma | Apr 2029 |
HIV (1) High-Grade Anal Intraepithelial Neoplasia (1) Post COVID-19 Condition, Unspecified (1) SARS CoV-2 Post-Acute Sequelae (1) Pneumonia (1) COVID-19 (1) HIV-1-infection (1) AML, Adult (1) High Grade Glioma (1)
small molecule (5), mixed (2)
Harvard School of Public Health (HSPH) (1) University of Wisconsin, Madison (1) Haukeland University Hospital (1) Mount Sinai Hospital, Canada (1) University of Oxford (1) Gilead Sciences (1) University of Miami (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.